Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rocuronium bromide + sevoflurane is a combination of two drugs used in anesthesia: - **Rocuronium bromide** is an aminosteroid, nondepolarizing neuromuscular blocking agent that works as a competitive antagonist at the nicotinic acetylcholine receptor at the neuromuscular junction, causing muscle paralysis and facilitating intubation or surgical relaxation[1][2][3][4][5]. - **Sevoflurane** is a volatile halogenated ether inhalational anesthetic agent, widely used to induce and maintain general anesthesia. It acts primarily by modulating multiple central nervous system ion channels, notably enhancing GABA-A receptor activity, resulting in CNS depression and unconsciousness. The combination is typically used during surgeries requiring muscle relaxation under general anesthesia, often with sevoflurane enhancing the neuromuscular blockade produced by rocuronium bromide, allowing lower doses of each[5]. Both are widely studied and approved components of anesthesia protocols, especially in pediatric and adult surgical anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rocuronium bromide + sevoflurane.